Peripheral Inflammatory Indexes Neutrophil/Lymphocyte Ratio (NLR) and Red Cell Distribution Width (RDW) as Prognostic Biomarkers in Advanced Solitary Fibrous Tumour (SFT) Treated with Pazopanib
Por:
Hidalgo-Ríos S., Carrillo-García J., Moura D.S., Stacchiotti S., López-Pousa A., Redondo A., Italiano A., Gutiérrez A., Grignani G., Hindi N., López-Guerrero J.-A., Muro X.G.D., Trufero J.M., Palmerini E., García A.S., Bernabeu D., Le Cesne A., Casali P.G., Blay J.-Y., Cruz Jurado J., Martin-Broto J.
Publicada:
1 ene 2022
Resumen:
Pazopanib was assessed prospectively in the GEIS-32 phase II study (NCT02066285) on advanced solitary fibrous tumour (SFT), resulting in a longer progression-free survival (PFS) and overall survival (OS) compared with historical controls treated with chemotherapy. A retrospective analysis of peripheral inflammatory indexes in patients enrolled into GEIS-32 was performed to evaluate their prognostic and predictive value. Patients received pazopanib 800 mg/day as the first antiangiogenic line. The impacts of baseline neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), and red cell distribution width (RDW) on PFS, OS, and Choi response were evaluated by univariate and multivariate analysis. Metastasis-free interval (MFI), mitotic count, and ECOG were also included as potential prognostic factors. Sixty-seven SFT patients, enrolled in this study, showed a median age of 63 years and a female/male distribution of 57/43. The median follow-up from treatment initiation was 16.8 months. High baseline NLR, PLR, and standardised RDW were significantly associated with worse PFS and OS. NLR, RDW, MFI, and mitotic count were independent variables for PFS, while RDW and ECOG were independent for OS. Further, NLR and mitotic count were independent factors for Choi response. High baseline NLR and RDW values were independent prognostic biomarkers for worse outcome in advanced SFT patients treated with pazopanib. © 2022 by the authors.
Filiaciones:
Hidalgo-Ríos S.:
Department of Clinical Pharmacology, University Hospital Virgen del Rocío, Sevilla, 41013, Spain
Carrillo-García J.:
Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, 28040, Spain
Medical Oncology Department, University Hospital General de Villalba, Madrid, 28400, Spain
Moura D.S.:
Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, 28040, Spain
Medical Oncology Department, University Hospital General de Villalba, Madrid, 28400, Spain
Stacchiotti S.:
Adult Mesenchymal and Rare Tumor Unit, Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 20133, Italy
López-Pousa A.:
Department of Medical Oncology, Sant Pau Hospital, Barcelona, 08041, Spain
Redondo A.:
Department of Medical Oncology, University Hospital La Paz, Institute for Health Research (IdiPAZ), Madrid, 28046, Spain
Italiano A.:
Department of Oncology, Institut Bergonié, Bordeaux, 33000, France
Gutiérrez A.:
Department of Hematology, University Hospital Son Espases, Palma, 07210, Spain
Grignani G.:
Sarcoma Unit, Division of Medical Oncology, Candiolo Cancer Institute, Candiolo, 10060, Italy
Hindi N.:
Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, 28040, Spain
Medical Oncology Department, University Hospital General de Villalba, Madrid, 28400, Spain
Medical Oncology Department, University Hospital Fundación Jiménez Díaz, Madrid, 28040, Spain
López-Guerrero J.-A.:
Laboratory of Molecular Biology, Fundación Instituto Valenciano de Oncología, Valencia, 46009, Spain
Muro X.G.D.:
Catalan Institute of Oncology, Institut d’Investigació Biomédica de Bellvitge, University of Barcelona, Barcelona, 08907, Spain
Trufero J.M.:
Department of Medical Oncology, University Hospital Miguel Servet, Zaragoza, 50009, Spain
Palmerini E.:
Chemotherapy Unit, Istituto Ortopedico Rizzoli, Bologna, 40136, Italy
García A.S.:
Department of Medical Oncology, Sant Pau Hospital, Barcelona, 08041, Spain
Bernabeu D.:
Musculoskeletal Imaging Section, University Hospital La Paz, Madrid, 28046, Spain
Le Cesne A.:
Department of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, 94805, France
Casali P.G.:
Adult Mesenchymal and Rare Tumor Unit, Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 20133, Italy
Blay J.-Y.:
Department of Medical Oncology, Centre Léon Bérard, Université Claude Bernard Lyon, Lyon, 69008, France
Cruz Jurado J.:
Department of Medical Oncology, University Hospital of Canarias, Tenerife, 38320, Spain
Martin-Broto J.:
Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, 28040, Spain
Medical Oncology Department, University Hospital General de Villalba, Madrid, 28400, Spain
Medical Oncology Department, University Hospital Fundación Jiménez Díaz, Madrid, 28040, Spain
All Open Access, Gold
|